Editora Creative eBooks, Год журнала: 2021, Номер unknown, С. 134 - 143
Опубликована: Янв. 1, 2021
Journal of Infection, Год журнала: 2021, Номер 84(1), С. 31 - 39
Опубликована: Ноя. 14, 2021
Язык: Английский
Процитировано
40
Pediatric Nephrology, Год журнала: 2022, Номер 38(4), С. 1159 - 1166
Опубликована: Сен. 22, 2022
Язык: Английский
Процитировано
28
Clinical and Experimental Pediatrics, Год журнала: 2023, Номер 66(5), С. 182 - 189
Опубликована: Апрель 18, 2023
Since coronavirus disease 2019 (COVID-19) became a global pandemic, concerns have arisen regarding the risks of COVID-19 in immunocompromised children and adolescents. Here we aimed to evaluate clinical outcomes severe pediatric patients. Previous studies reported that most adolescents receiving immunosuppressive medications presentations favorable similar those general population. Treatments access health services should not be interrupted these populations, continuous monitoring potential impact variant strains on risk patients is warranted.
Язык: Английский
Процитировано
10
Deleted Journal, Год журнала: 2025, Номер 22(1)
Опубликована: Май 2, 2025
Язык: Английский
Процитировано
0
International Journal of General Medicine, Год журнала: 2021, Номер Volume 14, С. 8097 - 8108
Опубликована: Ноя. 1, 2021
Abstract: Coronavirus disease 2019 (COVID-19) has been circulating in many countries around the world, characterized by long incubation period, strong infectivity, variability, high population susceptibility and diversified transmission methods. Its causative agent is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Compared with adult patients, clinical manifestations of COVID-19 children are often dominated mild or asymptomatic infections, but also important virus carriers play an role virus. In addition, some will show excessive inflammatory response experience serious complications such as multisystem (MIS-C). At present, research on still imperfect. This article review epidemiological characteristics, mechanism action, variant manifestations, auxiliary examinations treatment COVID-19, order to provide help for diagnosis, COVID-19. Keywords: children, mutation,
Язык: Английский
Процитировано
15
Reviews in Medical Virology, Год журнала: 2022, Номер 32(5)
Опубликована: Март 5, 2022
Abstract We aimed to study the outcomes of COVID‐19 in paediatric cancer patients. On 26 October 2021, we did a systematic search for relevant articles seven electronic databases followed by manual search. included patients aged ≤18 years. Event rates and 95% confidence interval (95%CI) were used report results. 21 papers after screening 2759 records. The pooled hospitalisation, intensive care unit (ICU) admission mortality 44% (95%CI: 30–59), 14% 9–21) 9% 6–12), respectively. Moreover, subgroup analysis revealed that high income countries had better compared upper middle lower terms hospitalisation 30% 17–46), 60% 29–84) 47% 36–58), ICU 7% 1–32), 13% 7–23) 18% 6–41), 3% 2–5), 12% 8–18) 8–20), order. In general, absence specific pharmacologic intervention prevent infection with scarcity vaccination coverage data among groups its impact, priority caution is required avoid SARS‐CoV‐2 Furthermore, our results highlight importance promoting facilities this vulnerable population low regions ensure quality during pandemic crisis.
Язык: Английский
Процитировано
10
Current Oncology, Год журнала: 2023, Номер 30(2), С. 2441 - 2456
Опубликована: Фев. 17, 2023
(1) Background: The COVID-19 global pandemic has impacted people worldwide with unique implications for vulnerable groups. In this cross-sectional study, we examined the impact of early on children undergoing active cancer treatment and their parents. (2) Methods: May 2020, 30 parents completed an online survey regarding child's care, perceived utility telemedicine, child parent mental health status. (3) Results: Most participants (87%) reported that they did not experience any changes to major treatments. Among those who using 78% be beneficial. Over half status was worse now than prior pandemic. Parent-reported anxiety scores were significantly higher care compared report same, t(25.99) = -3.04, p 0.005. (4) Conclusion: Child affected when pre-pandemic. Telemedicine appears a promising complement face-to-face meetings some families warrants further exploration.
Язык: Английский
Процитировано
5
Frontiers in Immunology, Год журнала: 2022, Номер 13
Опубликована: Авг. 3, 2022
Objectives We aimed to study the outcomes, severity, and seroconversion post SARS-CoV-2 infection in immunocompromised children adolescents treated at our center. Method For this observational study, all pediatric patients who had COVID-19 from Sep-22-2020 Nov-10-2021were identified by reviewing laboratory records. Their charts were reviewed determine clinical severity outcome. Blood samples drawn for anti-SARS-CoV-2 antibody assay. Serious (SVI) was defined if patient moderate, severe, or critical illness. A cutoff of 100 U/mL antibodies used categorize low high titer seroconversion. Results 263 with COVID-19; most (68%) symptomatic: 5% severe infection, 25% hospitalized, 12 required respiratory support, admitted ICU, five (2%) died. Multivariable analysis revealed several factors that predict SVI: Age above years (p=0.035), body mass index 95 th percentile (p=0.034), comorbid conditions (p=0.025), absolute neutrophil count ≤500(p=0.014) lymphocyte ≤300 (p=0.022). Levels spike obtained 173 a median 94 days (range, 14–300) after PCR diagnosis; them 142 (82%) seroconverted; lowest rate observed hematological malignancies (79%). Our univariable model showed following predictive titer: lower ANC, p=0.01; hematologic malignancy, p=0.023; receiving steroids last 14 days, p=0.032; time since chemotherapy immunosuppressive therapy less than 30 p=0.002; being on active 3 months prior p<0.001. Conclusions developed study. Mortality relatively patients. multivariable models multiple variables infections response infection. These observations may guide choice during best timing vaccination high-risk population.
Язык: Английский
Процитировано
6
Journal of Infection and Public Health, Год журнала: 2022, Номер 15(11), С. 1212 - 1224
Опубликована: Окт. 13, 2022
The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome 2 (SARS-CoV-2), has inflicted immense damage to countries, economies and societies worldwide. Authorized COVID-19 vaccines based on different platforms have been widely inoculated in adults, showing up 100% immunogenicity with significant efficacy preventing SARS-CoV-2 infections the occurrence of COVID-19. It also greatly slowed evolution variants, as shown clinical trials real-world evidence. However, total dosage for children is much smaller than that adults due limitations from parental concern vaccine safety, presenting a potential obstacle ending pandemic. not only increases risk multisystem inflammatory (MIS-C) children, but negatively affects children's psychology academics, indirectly hindering maintenance progress normal social order. Therefore, this article examines manifestations infected SARS-CoV-2, status vaccination against vaccination-related adverse events, unique immune mechanisms children. In particular, necessity challenges vaccinating were highlighted perspectives society family. summary, hesitancy unnecessary events after proven be infrequent, comprise mild symptoms, good prognosis.
Язык: Английский
Процитировано
6
Frontiers in Pediatrics, Год журнала: 2022, Номер 10
Опубликована: Фев. 10, 2022
To date, there's no evidence of an increased risk SARS-CoV-2 infection or more severe COVID-19 in patients with inflammatory bowel disease (IBD). However, whether alters the clinical course IBD treatment affects immunological response to is still under investigation, especially children.To assess serological children IBD, and evaluate impact on IBD.This prospective study enrolled (0-18 years) followed-up at University Hospital Padova for who acquired a confirmed between 02.2020 02.2021. The anti-SARS-CoV-2 S-RBD IgG titer was evaluated 3 months after compared that control group healthy matched age, sex, severity.Twelve (M = 5; median age 14 contracted during period. 11/12 were immunomodulatory (4/12 steroids; 6/12 azathioprine; 3/12 anti-TNFs; 2 vedolizumab; 1 ustekinumab). remained asymptomatic 4/12 caused mild remaining 8. Mean similar controls (27.3 ± 43.8 vs. 36.8 35.3 kAU/L, p ns). No experienced flares nor required gastroenterological support period.Children can mount protective humoral against SARS-CoV-2, which comparable their peers regardless ongoing treatment. This also supports favorable PIBD vice-versa.
Язык: Английский
Процитировано
4